Priovant (NASDAQ: ROIV) launched a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris (LPP), enrolling its first subjects in March 2026. LPP affects ~100,000 US adults and lacks FDA-approved treatments. Brepocitinib is already in late-stage development for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.
The FDA granted Priority Review to the DM NDA with a PDUFA target action date in Q3 2026; topline NIU data and a CS Phase 3 start are expected in H2 2026. Brepocitinib is a dual JAK1/TYK2 inhibitor.
Loading...
Loading translation...
Positive
Phase 2b/3 enrollment began in March 2026
Established late-stage program across four indications (LPP, DM, NIU, CS)
FDA granted Priority Review for DM NDA with PDUFA Q3 2026
Topline NIU data and CS Phase 3 start expected in H2 2026
Negative
LPP remains investigational; registrational efficacy not yet demonstrated
Commercial prospects depend on upcoming DM PDUFA and other trial readouts
Market Context
This announcement expands brepocitinib into a seamless Phase 2b/3 trial for lichen planopilaris, a c...
Analysis
This announcement expands brepocitinib into a seamless Phase 2b/3 trial for lichen planopilaris, a condition affecting approximately 100,000 U.S. adults with no FDA-approved therapies. It adds a fourth late-stage indication alongside DM, NIU, and CS, with a Priority Review PDUFA date in Q3 2026. Investors may track trial progress, regulatory outcomes, and the clustering of Phase 3 milestones in the second half of 2026.
Key Figures
Disease prevalence:approximately 100,000 adults in the United StatesPhase 2b/3 trial:Phase 2b/3Fourth indication:4th indication+5 more
8 metrics
Disease prevalenceapproximately 100,000 adults in the United StatesLichen planopilaris affected population
Phase 2b/3 trialPhase 2b/3Seamless potentially registrational LPP study
Fourth indication4th indicationBrepocitinib late-stage development program
Priority ReviewPriority Review grantedFDA review status for brepocitinib NDA in DM
PDUFA timingQ3 2026PDUFA target action date for DM NDA
Phase 3 NIU data timingsecond half of 2026Topline Phase 3 NIU data expected
CS Phase 3 startsecond half of 2026Phase 3 study initiation in cutaneous sarcoidosis
First LPP subjectsMarch 2026First subjects enrolled in LPP Phase 2b/3 trial
Key Terms
lichen planopilaris, new drug application (nda), priority review, pdufa, +4 more
8 terms
lichen planopilarismedical
"Priovant today announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP)"
Lichen planopilaris is a chronic inflammatory scalp condition that destroys hair follicles and leads to permanent, patchy hair loss; it is considered a form of scarring alopecia. Investors watch it because treatments are limited and any new drug, device, or diagnostic that can stop or reverse the scarring could capture a steady market—think of it as fixing leaky foundations rather than just trimming visible damage.
new drug application (nda)regulatory
"granted Priority Review to brepocitinib’s New Drug Application (NDA) for DM"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
priority reviewregulatory
"The U.S. Food and Drug Administration (FDA) recently granted Priority Review"
Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.
pdufaregulatory
"assigned a Prescription Drug User Fee Act (PDUFA) target action date"
PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.
phase 2b/3medical
"A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP"
A phase 2b/3 trial is a combined late-stage clinical study that first refines the best dose and measures how well a treatment works (phase 2b) then expands to a larger, definitive test of safety and effectiveness needed for regulatory approval (phase 3). For investors, results from a phase 2b/3 act like a dress rehearsal that turns into opening night: positive, well-controlled outcomes substantially raise the chance of approval and future sales, while failures can sharply reduce a drug’s value.
phase 3medical
"Topline Phase 3 data in NIU and Phase 3 study initiation in CS"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
orphan conditionsmedical
"developing brepocitinib in highly morbid orphan conditions with limited treatment options"
Rare medical disorders that affect a very small number of people compared with common diseases. They matter to investors because treatments for these conditions often receive special regulatory incentives—like faster reviews, fee waivers and market exclusivity—which can make developing a drug for a small patient group economically attractive; think of it as serving a tiny, underserved market where a successful product can command higher prices and steadier demand.
dual jak1/tyk2 inhibitionmedical
"distinctive mechanistic benefits of dual JAK1/TYK2 inhibition"
Dual JAK1/TYK2 inhibition is a drug mechanism that blocks two enzymes, JAK1 and TYK2, which help cells pass along immune system signals that can cause inflammation. For investors, it matters because medicines using this approach aim to reduce autoimmune inflammation or overactive immune responses, potentially offering stronger effects than targeting one enzyme alone but also carrying risks like increased infection or regulatory scrutiny—similar to turning down two dials on a noisy control panel to quiet a system.
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need
LPP marks the fourth indication in brepocitinib’s expanding late-stage development program
Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication
A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026
DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Priovant today announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States. LPP inflammation targets the stem cell-rich bulge region of the hair follicle (the permanent portion responsible for hair growth), resulting in generally irreversible hair loss and permanent scarring. LPP is also associated with other burdensome symptoms, including pain, burning, itching and scaling, and an increased risk of comorbidities such as other autoimmune diseases and skin cancers. There are currently no FDA-approved therapies to treat LPP.
“Lichen planopilaris (LPP) is what my colleagues and I refer to as a ‘trichologic emergency,’” said Dr. Kristen Lo Sicco, Chief of the Skin and Cancer Unit at NYU Langone Health, Board Member of the Scarring Alopecia Foundation, and Associate Professor of Dermatology at the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine. “Absent early diagnosis and aggressive intervention, patients experience rapid hair loss that is generally irreversible, leaves permanent scarring, and is often accompanied by erythema, scaling, pain, itching and burning sensations. Untreated LPP also leads to increased risk of skin cancers and other comorbidities. Efficacious FDA-approved treatments are urgently needed.”
Priovant recently began enrolling subjects in a seamless Phase 2b/3 study of brepocitinib in LPP, with the first subjects enrolled in March 2026. This program marks Priovant’s fourth indication in late-stage clinical development, alongside dermatomyositis (DM), non-infectious uveitis (NIU) and cutaneous sarcoidosis (CS). The U.S. Food and Drug Administration (FDA) recently granted Priority Review to brepocitinib’s New Drug Application (NDA) for DM and assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026. Topline Phase 3 data in NIU and Phase 3 study initiation in CS are expected in the second half of calendar year 2026.
“Expanding brepocitinib into lichen planopilaris continues our strategy of developing brepocitinib in highly morbid orphan conditions with limited treatment options and distinctive mechanistic benefits of dual JAK1/TYK2 inhibition,” said Ben Zimmer, Priovant CEO. “Moreover, as we look ahead to our expected product launch in DM in September, we see LPP as a strategic fit into a multi-indication rheum-derm rare disease franchise anchored by DM, with overlapping prescriber bases and thought leaders.”
About Priovant
Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a first-in-class, selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12 and IL-23—with a single, targeted, once-daily oral therapy. Brepocitinib recently generated positive Phase 3 data in dermatomyositis. The New Drug Application for brepocitinib in dermatomyositis is under review at FDA. Brepocitinib is also being evaluated in a Phase 3 program in non-infectious uveitis, a Phase 3 program in cutaneous sarcoidosis beginning in the second half of calendar year 2026, and a Phase 2b/3 program in lichen planopilaris. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.
What did Priovant (ROIV) announce about brepocitinib in LPP on April 2, 2026?
Priovant announced a seamless Phase 2b/3 trial for brepocitinib in LPP, with first subjects enrolled in March 2026. According to the company, this expands brepocitinib into a fourth late-stage indication targeting a ~100,000-patient US population.
How large is the LPP patient population Priovant (ROIV) cited for brepocitinib development?
Priovant estimates LPP affects approximately 100,000 adults in the United States. According to the company, LPP causes scarring hair loss and currently has no FDA-approved therapies.
What regulatory progress did Priovant (ROIV) report for brepocitinib in dermatomyositis (DM)?
The FDA granted Priority Review for brepocitinib's DM NDA with a PDUFA target action date in Q3 2026. According to the company, this supports an expected product launch in DM in September 2026.
When does Priovant (ROIV) expect key brepocitinib readouts for NIU and CS in 2026?
Priovant expects topline Phase 3 data in non-infectious uveitis and a Phase 3 start in cutaneous sarcoidosis in H2 2026. According to the company, both milestones are projected in the second half of calendar year 2026.
What is the mechanism of action for brepocitinib that Priovant (ROIV) highlights?
Brepocitinib is a dual JAK1/TYK2 inhibitor that targets inflammatory signaling pathways. According to the company, this mechanism provides a rationale for use across multiple rare rheum-derm indications.
What immediate development milestone did Priovant (ROIV) achieve for brepocitinib in LPP?
Priovant enrolled the first subjects into a seamless Phase 2b/3 LPP trial in March 2026. According to the company, initial enrollment marks the transition to a potentially registrational program.
